targeted therapy

Medical oncologist Dr. Joshua Reuss, an expert in lung cancer, mesothelioma and thymoma, and pulmonologist Dr. Rebecca Krochmal, an expert in benign and malignant airway and pleural disease, both with MedStar Georgetown  University Hospital in Washington, D.C., address questions related to finding and treating lung cancer.

To listen to and download all episodes, visit: https://www.medstarhealth.org/news-an....

Learn more about Dr. Reuss: https://www.medstarhealth.org/doctors....
Learn more about Dr. Krochmal: https://www.medstarhealth.org/doctors....

For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

This episode features an interview with Dr. Genevieve Neal-Perry, MD, PhD, professor and chair at the UNC School of Medicine Department of Obstetrics and Gynecology, and lead investigator on a study investigating Astellas Pharma’s fezolinetant (Veozah), which received FDA approval in May this year for the treatment of moderate to severe vasomotor symptoms due to menopause.

It’s the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat vasomotor symptoms, which include hot flashes and night sweats, associated with menopause.

Dr. Neal-Perry spoke about some of the latest trial data for fezolinetant that was presented at the recent Annual Meeting of The Menopause Society. This includes the effect of the drug on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history from pooled data from two randomized Phase III studies. It also included safety data over a period of 52 weeks from three randomized Phase III studies (SKYLIGHT 1, 2 and 4).

It is estimated that around 60 to 80 percent of women experience vasomotor symptoms during or after the menopausal transition. They can have a significant impact on daily activities and overall quality of life.

Tune into the episode to hear from Dr. Neal-Perry about vasomotor symptoms associated with menopause and the new trial data for fezolinetant.

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Discover the power of an integrative approach to cancer treatment on the latest episode of the Integrative Cancer Solutions podcast with Dr. Karlfeldt. This informative podcast focuses on the need for alternative cancer treatments and invites listeners to learn about powerful integrative and holistic methods that may help fight cancer. Dr. Karlfeldt shares his personal experience of losing his father to colon cancer, which led him to focus on cancer prevention and healing. From discussing the limitations of conventional oncology to the importance of finding an oncologist who educates and involves patients in the healing process, this podcast covers it all. Learn about cutting-edge cancer therapies like photodynamic therapy and the use of anti-inflammatory and antioxidant therapies to support overall health and wellness. Tune in to discover the importance of maintaining healthy habits, adopting a positive mindset, and asking how cancer can serve as a tool for growth and self-improvement. Don't miss out on this powerful episode. Listen now to Integrative Cancer Solutions with Dr. Karlfeldt.

- Integrative cancer solutions
- Dr. Karlfeldt's personal experience
- Naturopathic oncology
- Limitations of conventional oncology
- Empowering the patient
- Addressing cancer from various angles
- Maintaining healthy habits
- Cancer as a wake-up call
- Understanding cancer stem cells
- Combining traditional and terrain therapies
- Calming cancer stem cell activation
- Photodynamic therapy
- Education and prevention
- Comprehensive and integrative approach
- The Karlfeldt Center 
- Live consultation with cancer patient next week

KEY POINTS

[0:0:32] Astonishingly, integrative and holistic approaches to cancer treatment have been shown to drastically improve survival rates and save lives.

[0:6:48] By taking a holistic approach to treating cancer, Naturopathic Oncology has been proven to dramatically improve patient outcomes - not just physically, but emotionally and spiritually too!

[0:7:19] By shifting your mindset from "why is this happening to me" to "how can this challenge serve me," you can unlock a world of powerful possibilities and experience growth, healing, and profound appreciation.

[0:9:36] Cancer is a devastating, multifaceted disease that demands comprehensive and expert treatment for the best chance of success.

[0:14:38] Cancer can be seen as a powerful catalyst that inspires individuals to re-examine and transform their mental, spiritual, and physical health.

[0:17:47] Surgery can cause cancer to spread more aggressively due to the disruption of tumor coordination and the activation of cancer stem cells - a potentially life-threatening consequence. To minimize this risk and ensure a healthier recovery, pre-surgery treatments that address the body as a whole are essential.

[0:19:25] Cancer stem cells, which can resist traditional treatments, have the potential to spark tumor initiation and growth - making anti-inflammatory and antioxidant strategies paramount for minimizing their activation and fighting cancer.

[0:24:9] Experience the power of natural remedies with PolyMVA, curcumin, vitamin C, ozone, and laser therapy – scientifically proven to reduce inflammation and invigorate stem cell activity!

[0:27:32] PDT is revolutionizing cancer treatment with its awe-inspiring ability to eradicate cancer cells and bolster the body's natural defense system using only the power of light!

[0:30:0] Utilizing innovative photodynamic therapy and stem cells/exosome-like vesicles, new breakthroughs in cancer treatment are being achieved, drastically increasing the efficacy of photosensitizers to effectively target and destroy tumors.

[0:31:27] By combining photodynamic therapy with hyperbaric oxygen therapy, patients can experience powerful oxidation benefits, dramatically increasing the oxygen content in their tissue.

[0:33:47] Consistently engaging in healthy habits can significantly reduce the risk of cancer recurrence, whereas a lapse in diet and exercise can have detrimental effects.

Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. For more information about products and services discussed in this podcast, please visit www.integrativecancersolutions.com. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com.

This episode features an interview with Manu Garg, VP, Head of Healthcare Consulting at Definitive Healthcare. Sarah and Manu discussed the transformative role of healthcare commercial intelligence in the industry today, and how machine learning (ML) and artificial intelligence (AI) are changing care delivery for patients. 

As new drug development is increasingly focused on targeted therapies for rare diseases and other indications with limited patient pools, healthcare commercial intelligence can help companies find their target market and help direct resources. Manu explained how both large and small pharmas, biotechs and medtechs can benefit from Definitive Healthcare’s SaaS-based tools.

Manu explained how AI is helping to predict tumor mutations so that cell and gene therapies can be targeted to individual patient’s needs, realizing the true promise of “personalized medicine.” He also discussed why the healthcare sector needs to adopt new ways of using patient-generated device-based health data to bring care to patients when and where they need it.

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Treatment of prostate cancer has changed dramatically over the years, with  multiple treatment options including chemotherapy, refined hormonal therapies, radiotherapies, surgery and others currently available, depending on the patient and their disease.

Dr Sakir Mutevelic, Chief Medical Officer at Curium, has witnessed the tremendous progress in cancer treatment options and the increased survival rate that goes with them.  Today, we’re talking with him about an investigational treatment for metastatic castration resistant prostate cancer in development at Curium, that could be a valuable new asset in disease management.

Information for clinicians about the Eclipse trial is available here.

For patients, a web portal with more information is available here.

All trial data is available at:  https://clinicaltrials.gov/ct2/show/NCT05204927

In this episode, Ayesha discussed the FDA approval of two new immunotherapies, including Janssen/Johnson & Johnson’s bispecific antibody Tecvayli for the treatment of relapsed or refractory multiple myeloma. The drug is the first bispecific T cell antibody to be approved in the US. It is indicated as a fifth line treatment for multiple myeloma patients who have received four or more prior treatments. Find out more about the bispecific antibody and about trials evaluating it in combination with other drugs to potentially move up its treatment line.

Ayesha also talked about the FDA approval of AstraZeneca’s immunotherapy Imjudo for hepatocellular carcinoma (HCC), which is the most common type of liver cancer. The drug is indicated for use in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi in adult patients with unresectable HCC. The new drug combination will be going up against Roche’s combo of Tecentriq and Avastin, which recently became the standard of care for HCC. Despite this, the Imjudo and Imfinzi approval offers another promising treatment option for HCC patients and is the first dual immunotherapy treatment regimen for this indication.

Read the full articles here:

Multiple Myeloma Drug Tecvayli Becomes First FDA-Approved Bispecific T Cell Antibody

AstraZeneca’s Immunotherapy Imjudo (tremelimumab) Wins FDA Approval for Liver Cancer

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

It’s been a while! I think we will call this the second season as it seems fitting as I head into another season of battling cancer. 

Devastated and angry are just two of the words that come to mind. But also with that come to surrender and faith. 

Thank you for being on the journey with me so far. Tag along as I fight cancer again.

If you enjoyed this episode, make sure and give us a five star rating  and leave us a review on iTunes, Podcast Addict, Podchaser and Castbox.

Sign up for the next DAC Bootcamp

Follow me on Social Media:

Amy on IG

Amy on Facebook

Resources:

AmyLedin.com

Lean Bodies Consulting (LBC)

LBC University

#5for50 #5for50FamilyEdition #AmyLedin #AmyLedin.com #ErikLedin #LeanBodiesConsulting #LBC #Kamele #KamelePerez

DISCLAIMER: The opinions, beliefs, and viewpoints expressed by the hosts and guests on this podcast do not necessarily represent or reflect the official policy, opinions, beliefs, and viewpoints of Disenyo.co LLC and its employees.

In this episode,  Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including:  

• Germline and somatic mutation testing
• PARP inhibition in earlier stage disease
• PARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapy
• PARP inhibition in taxane-sensitive patients

Presenters:

Wassim Abida, MD, PhD
Assistant Member
Assistant Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Joaquin Mateo, MD, PhD
Group Leader
Prostate Cancer Translational Research
Vall d'Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3h1T5oR

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:

• Germline and somatic mutation testing
• Managing adverse events with PARP inhibitors
• Resistance to PARP inhibitors
• Implications of monoallelic vs biallelic BRCA mutations
• ATM mutations and PARP inhibitor sensitivity

Presenters:

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/2P31ZqF

In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including:

• What is your preferred regimen for neoadjuvant therapy in patients with resectable disease?
• How do you sequence therapy for patients with metastatic pancreatic cancer?
• How can you manage a patient who develops significant diarrhea with FOLFIRINOX?
• Are cisplatin and oxaliplatin equally efficacious for patients with BRCA-mutant disease?
• How should maintenance olaparib be used?

Presenters:

Michael J. Pishvaian, MD, PhD  
Associate Professor of Oncology
Director, Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
NCR Kimmel Cancer Center at Sibley Memorial Hospital
John Hopkins University School of Medicine
Washington, DC

Rachna Shroff, MD
Associate Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

 Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Ipsen Group.

Link to full program:
http://bit.ly/314BALT

Proton Therapy, Targeted Therapy, and innovations in Pediatric Cancer! September is Pediatric Cancer Awareness Month so join us on LL&P as we sit down with Dr. Joanna Mack of Hematology/Oncology at Arkansas Children's to discuss exciting and emerging tech and ways to support the brave kids fighting and beating cancer!

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

• Optimal testing for RET fusions
• DNA NGS vs RNA NGS
• Molecular testing workflows
• Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
• Common toxicities with new selective RET inhibitors
• Interdisciplinary communication between medical oncologists and pathologists

Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:

• Whether testing for MET  exon 14 status should be standard of care
• Parallel vs sequential testing by DNA-based vs RNA-based NGS
• Co-occurring driver mutations in patients with METex14 mutation–positive NSCLC
• Optimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapy
• EMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinib

Presenters:
Luis Paz-Ares, MD, PhD 
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Link to full program, including associated downloadable slidesets:  https://bit.ly/2ExadCf

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:

• Best practices in testing for NTRK fusions in solid tumors
• Optimal use of approved TRK inhibitors
• Key adverse events with TRK inhibitors and management strategies
• Emerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agents

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics  
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Pashtoon Kasi, MD
Assistant Professor
College of Medicine and Oncology
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

Content based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.

Link to full program: https://bit.ly/2PN0BWh

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv